Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsManagement of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guidelinePhosphate control in dialysisPlasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational StudyTrends in the incidence of intestinal perforation in US dialysis patients (1992-2005).Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabilitySevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials.Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case reportSevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.Vascular and valvular calcification in chronic peritoneal dialysis patients.Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.Next-generation phosphate binders: focus on iron-based binders.Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.Advances in pharmacotherapy for secondary hyperparathyroidism.The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects
P2860
Q24234036-23870883-6896-4680-BA73-F0EEFCD31EE7Q26866391-D24D4D98-38D2-48B8-99A3-51380BC75EC2Q27025339-2888A827-759C-4C07-BD9D-8A35344958CFQ28535870-AFE081B7-9F9B-4902-B3FD-859F134470B4Q33980629-4332C1FB-B78A-4926-8021-C57902F31536Q34213692-A025A9D2-0E09-4C59-A3BC-D8F783D25798Q34505136-DA054D4A-E807-498C-9F93-13CA942634DCQ34885173-2ABA8C95-9486-40BA-8A5A-71E61E579882Q35730847-332B92DD-12A5-41F5-93D9-7F6586A12134Q36443804-C2F8D8F2-862B-4DF9-8FB9-D2A353661071Q37171642-FB84E592-55DB-459A-856D-F8979BF2BD4FQ37567574-4877F62B-F094-46F2-85D3-9DFCC5C6DA3AQ37914009-AF1234CC-F8EF-43B7-AB95-CEE3738252DBQ38202179-E8A901A3-C216-4159-B91A-BA9C9B93452CQ38213502-3F31B1CD-2C49-4364-B49F-2B81D88ED728Q38219038-85607821-BA28-474B-A84A-D44DEC2A86A5Q38229088-8B2D0D90-A1AE-4001-9085-B80B2A7618A5Q38544533-EAA69F4A-557E-4D55-B7B4-9E8DA527695CQ38819231-4F1D7A3F-21B3-4083-8260-72A359059006Q39220825-9A4840D3-3154-4E94-815D-06EFF9636A2DQ43427754-59158B14-6F15-4286-A219-0E79B16B05A2Q44853372-BCFA215B-68EF-45B9-A564-292E61594311Q49846193-DAFD411F-15CD-43B3-B68C-195E54F5F15AQ57219101-5E99023E-CB94-48B3-B147-174A90537B83
P2860
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@en
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@nl
type
label
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@en
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@nl
prefLabel
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@en
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of sevelam ...... tients on peritoneal dialysis.
@en
P2093
Ajay Duggal
Alison Kelly
Flavia Caputo
James G Heaf
Lukas Foggensteiner
Pieter Evenepoel
Rafael Selgas
Scott Chasan-Taber
Stanley Fan
P2860
P304
P356
10.1093/NDT/GFN488
P407
P577
2008-09-27T00:00:00Z